Arcus Biosciences RCUS Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's change in deferred revenue?
- Arcus Biosciences (RCUS) reported change in deferred revenue of -$17M in Q1 2026.
- How has Arcus Biosciences's change in deferred revenue changed year-over-year?
- Arcus Biosciences's change in deferred revenue increased by 39.3% year-over-year, from -$28M to -$17M.
- What is the long-term trend for Arcus Biosciences's change in deferred revenue?
- Over 3 years (2021 to 2025), Arcus Biosciences's change in deferred revenue has grown at a -13.3% compound annual growth rate (CAGR), from -$368M to -$240M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.